Cholera vaccines

Journal of Travel Medicine

Volumn 8, Issue 2, 2001, Pages 82-091

  Ryan, Edward T ^a   Calderwood, Stephen B ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLERA VACCINE;

CHOLERA; CLINICAL FEATURE; DISEASE TRANSMISSION; DRUG APPROVAL; DRUG EFFICACY; FECES; FOOD AND DRUG ADMINISTRATION; FOOD CONTAMINATION; HUMAN; IMMUNOGENICITY; INCIDENCE; INFECTION RISK; PRESCHOOL CHILD; REVIEW; TRAVEL; TRAVELLER DIARRHEA; VIBRIO CHOLERAE;

EID: 0035024352     PISSN: 11951982     EISSN: None     Source Type: Journal    
DOI: 10.2310/7060.2001.24300     Document Type: Review

References (118)

1. Sakazaki R, Tamura K. Somatic antigen variation in Vibrio cholerae. Jpn J Med Sci Biol 1971; 24:93-100
2. Pal SC. Laboratory Diagnosis. In: Barua D, Greenough WB III, eds. Cholera. New York: Plenum Medical Book Company, 1992:238-240.
3. Sarkar BL, De SP, Sircar BK, et al. Polymyxin B sensitive strains of Vibrio cholerae non-O1 from recent epidemic in India [Letter]. Lancet 1993; 341:1090.
4. Cholera Working Group, International Centre for Diarrhoeal Diseases Research, Bangladesh. Large epidemic of cholera-like disease in Bangladesh caused by Vibrio cholerae O139 synonym Bengal. Lancet 1993; 342:387-390.
5. Institute of Medicine. New vaccine development: establishing priorities. Volume II, Diseases of importance in developing countries. Washington, DC: National Academy Press, 1986.
6. Mintz ED, Popovic T, Blake PA. Transmission of Vibrio cholerae O1. In: Wachsmuth IK, Blake PA, Olsvik O, eds. Vibrio cholerae and cholera: molecular to global perspectives. Washington DC: American Society for Microbiology Press, 1994:345-356.
7. Cash RA, Music SI, Libonati JP, et al. Response of man to infection with Vibrio cholerae. II. Protection from illness afforded by previous disease and vaccine. J Infect Dis 1974; 130:325-333.
8. Gitelson S. Gastrectomy, achlorhydria and cholera. Isr J Med Sci 1971; 7:663-667.
9. Feachem RG. Environmental aspects of cholera epidemiology. III. Transmission and control. Trop Dis Bull 1982;79:1-17.
10. Cash RA, Music SI, Libonati JP, et al. Response of man to infection with Vibrio cholerae. 1. Clinical, serologic, and bacteriologic responses to a known inoculum. J Infect Dis 1974; 129:45-52.
11. Bart KJ, Huq Z, Khan M, Mosley WH. Seroepidemiologic studies during a simultaneous epidemic of infection with El Tor Ogawa and classical Inaba Vibrio cholerae. J Infect Dis 1970; 121(Suppl 121):517-524.
12. Barua D, Paguio AS. ABO blood groups and cholera. Ann Hum Biol 1977; 4:489-492.
13. Sircar BK, Dutta P, De SP, et al. ABO blood group distributions in diarrhoea cases including cholera in Calcutta. Ann Hum Biol 1981; 8:289-291.
14. Lindenbaum J, Greenough WB, Islam MR. Antibiotic therapy of cholera. Bull World Health Organ 1967; 36:871-883.
15. Ryan ET, Dhar U, Khan WA, et al. Mortality, morbidity and microbilogy of endemic cholera in Dhaka, Bangladesh. Am J Trop Mod Hyg (in press).
16. Wittlinger F, Steffen R, Watanabe H, Handszuh H. Risk of cholera among Western and Japanese travelers. J Travel Med 1995; 2:154-158.
17. Anonymous. Cholera associated with an international airline flight, 1992. MMWR 1992; 41:134-135.
18. Anonymous. Summary of Notifiable Diseases, United State, 1998. MMWR 1999; 47:ii-92.
19. Sanchez JL, Taylor DN. Cholera [see Comments]. Lancet 1997: 349:1825-1830.
20. Taylor DN, Rizzo J, Meza R, et al. Cholera among Americans living in Peru. Clin Infect Dis 1996; 22:1108-1109.
21. Steffen R, Rickenbach M, Wilhelm U, et al. Health problems after travel to developing countries. J Infect Dis 1987; 156:84-91.
22. Levine MM, Pierce NF. Immunity and vaccine development. In: Barua D, Greenough WB III, eds. Cholera. New York: Plenum Medical Book Company, 1992:285-327.
23. Szu SC, Gupta R, Robbins JB. Induction of serum vibriocidal antibodies by O-specific polysaccharide-protein conjugate vaccines for prevention of cholera. In: Wachsmuth IK, Blake PA, Olsvik O, eds. Vibrio cholerae and cholera, molecular to global perspectives. Washington, DC: American Society for Microbiology Press, 1994:381-394.
24. Levine MM, Tacket CO. Recombinant live cholera vaccines. In: Wachsmuth IK, Blake PA, Olsvik O, eds. Vibrio cholerae and cholera: molecular to global perspectives. Washington, DC: American Society for Microbiology Press, 1994:395-414.
25. Holmgren J, Osek J, Svennerholm A-M. Protective oral cholera vaccine based on a combination of cholera toxin B subunit and inactivated cholera vibrios. In: Wachsmuth IK, Blake PA, Olsvik O, eds. Vibrio cholerae and cholera: molecular to global perspectives. Washington, DC: American Society for Microbiology Press, 1994:415-424.
26. Clemens J, Spriggs D, Sack D. Public health considerations for the use of cholera vaccines in cholera control programs. In: Wachsmuth IK, Blake PA, Olsvik O, eds. Vibrio cholerae and cholera: molecular to global perspectives. Washington, DC: American Society for Microbiology Press, 1994:425-142.
27. Kaper JB, Morris JGJ, Levine MM. Cholera [published erratum appears in Clin Microbiol Rev 1995 Apr;8(2):316]. Clin Microbiol Rev 1995; 8:48-86.
28. Yardley JH, Keren DF, Hamilton SR, Brown GD. Local (immunoglobulin A) immune response by the intestine to cholera toxin and its partial suppression with combined systemic and intra-intestinal immunization. Infect Immun 1978; 19:589-597.
29. Svennerholm AM, Hanson LA, Holmgren J, et al. Different secretory immunoglobulin A antibody responses to cholera vaccination in Swedish and Pakistani women. Infect Immun 1980; 30:427-430.
30. Mosley WH, Ahniad S, Benenson AS, Ahmed A. The relationship of vibriocidal antibody titre to susceptibility to cholera in family contacts of cholera patients. Bull World Health Organ 1968; 38:777-785.
31. Mosley WH, Benenson AS, Barui R. A serological survey for cholera antibodies in rural east Pakistan. 1. The distribution of antibody in the control population of a cholera- vaccine field-trial area and the relation of antibody titre to the pattern of endemic cholera. Bull World Health Organ 1968; 38:327-334.
32. Mosley WH, McCormack WM, Ahmed A, et al. Report of the 1966-1967 cholera vaccine field trial in rural East Pakistan. 2. Results of the serological surveys in the study population - the relationship of case rate to antibody titre and an estimate of the inapparent infection rate with Vibrio cholera. Bull World Health Organ 1969;40:187-197.
33. Glass RI, Svennerholm AM, Khan MR, et al. Seroepidemiological studies of El Tor cholera in Bangladesh: association of serum antibody levels with protection. J Infect Dis 1985; 151:236-242.
34. Mosley WH, Aziz KM, Mizanur RA, et al. Report of the 1966-1967 cholera vaccine trial in rural East Pakistan. Bull World Health Organ 1972; 47:229-238.
35. Mosley WH, Aziz KM, Rahman AS, et al. Field trials of monovalent Ogawa and Inaba cholera vaccines in rural Bangladesh - three years of observation. Bull World Health Organ 1973; 49:381-387.
36. Azurin JC, Cruz A, Pesigan TP, et al. A controlled field trial of the effectiveness of cholera and cholera El Tor vaccines in the Philippines. Bull World Health Organ 1967; 37:703-727.
37. Oseasohn RO, Benenson AS, Fahimuddin M. Field trial of cholera vaccine in rural East Pakistan. Lancet 1965; i:450-453.
38. Pal SC, Deb BC, Sen GP, et al. A controlled field trial of an aluminum phosphate-adsorbed cholera vaccine in Calcutta. Bull World Health Organ 1980; 58:741-745.
39. Saroso JS, Bahrawi W, Witjaksono H, et al. A controlled field trial of plain and aluminium hydroxide-adsorbed cholera vaccines in Surabaya, Indonesia, during 1973-1975. Bull World Health Organ 1978; 56:619-627.
40. Gupta RK, Taylor DN, Bryla DA, et al. Phase 1 evaluation of Vibrio cholera O1, serotype Inaba, polysaccharide-cholera toxin conjugates in adult volunteers. Infect Immun 1998; 66:3095-3099.
41. Tacket CO, Clemens J, Kaper JB. Cholera vaccines. In: Ellis RW, ed. Vaccine: new approach in immunological problems. Boston: Buttersworth, 1995:53-68.
42. Sommer A. Ineffectiveness of cholera vaccination as an epidemic control measure. Lancet 1972; i:1232-1235.
43. World Health Organization. International Health Regulations. Second Annotated Edition. Geneva: World Health Organization, 1974.
44. Wiedermann G, Jong EC. Vaccine-preventable diseases. In: DuPont HL, Steffen R, eds. Textbook of travel medicine and health. Hamilton, Ontario: B.C. Decker, Inc., 1997:143-154.
45. Quiding M, Nordstrom I, Kilander A, et al. Intestinal immune responses in humans. Oral cholera vaccination induces strong intestinal antibody responses and interferon-gamma production and evokes local immunological memory. J Clin Invest 1991; 88:143-148.
46. Svennerholm AM, Jertborn M, Gothefors L, et al. Mucosal antitoxic and antibacterial immunity after cholera disease and after immunization with a combined B subunit-whole cell vaccine. J Infect Dis 1984; 149:884-893.
47. Black RE, Levine MM, Clements ML, et al. Protective efficacy in humans of killed whole-vibrio oral cholera vaccine with and without the B subunit of cholera toxin. Infect Immun 1987; 55:1116-1120.
48. Clemens JD, Sack DA, Harris JR, et al. Field trial of oral cholera vaccines in Bangladesh. Lancet 1986; 2:124-127.
49. Clemens JD, Sack DA, Harris JR, et al. Field trial of oral cholera vaccines in Bangladesh: results from three- year follow-up [see Comments]. Lancet 1990; 335:270-273.
50. Clemens JD, Sack DA, Harris JR, et al. ABO blood groups and cholera: new observations on specificity of risk and modification of vaccine efficacy. J Infect Dis 1989; 159:770-773.
51. Clemens JD, Sack DA, Harris JR, et al. Cross-protection by B subunit-whole cell cholera vaccine against diarrhea associated with heat-labile toxin-producing enterotoxigenic Escherichia coli: results of a large-scale field trial. J Infect Dis 1988; 158:372-377.
52. Peltola H, Siitonen A, Kyronseppa H, et al. Prevention of travellers' diarrhoea by oral B-subunit/whole-cell cholera vaccine. Lancet 1991; 338:1285-1289.
53. Clemens JD, Sack DA, Harris JR, et al. Impact of B subunit killed whole-cell and killed whole-cell-only oral vaccines against cholera upon treated diarrhoeal illness and mortality in an area endemic for cholera. Lancet 1988; 1:1375-1379.
54. Levine MM, Svennerholm A-M. Future enteric vaccines. In: DuPont HL, Steffen R, eds. Textbook of travel medicine and health. Hamilton, Ontario: B.C. Decker, Inc., 1997:169-177.
55. Begue RE, Castellares G, Cabezas C, et al. Immunogenicity in Peruvian volunteers of a booster dose of oral cholera vaccine consisting of whole cells plus recombinant B subunit. Infect Immun 1995; 63:3726-3728.
56. Begue RE, Castellares G, Ruiz R, et al. Community-based assessment of safety and immunogenicity of the whole cell plus recombinant B subunit (WC/rBS) oral cholera vaccine in Peru. Vaccine 1995; 13:691-694.
57. Sanchez JL, Vasquez B, Begue RE, et al. Protective efficacy of oral whole-cell/recombinant-B-subunit cholera vaccine in Peruvian military recruits [see Comments]. Lancet 1994; 344:1273-1276.
58. Jertborn M, Svennerholm AM, Holmgren J. Intestinal and systemic immune responses in humans after oral immunization with a bivalent B subunit-O1/O139 whole cell cholera vaccine. Vaccine 1996; 14:1459-1465.
59. Trach DD, Clemens JD, Ke NT, et al. Field trial of a locally produced, killed, oral cholera vaccine in Vietnam [see Comments]. Lancet 1997; 349:231-235.
60. Owen RL, Pierce NF, Apple RT, Gray WC Jr. M cell transport of Vibrio cholerae from the intestinal lumen into Peyer's patches: a mechanism for antigen sampling and for microbiological transepithelial migration.J Infect Dis 1986; 153:1108-1118.
61. Jonson G, Svennerholm AM, Holmgren J. Vibrio cholerae expresses cell surface antigens during intestinal infection which are not expressed during in vitro culture. Infect Immun 1989; 57:1809-1815.
62. Richardson K, Kaper JB, Levine MM. Human immune response to Vibrio cholerae O1 whole cells and isolated outer membrane antigens. Infect Immun 1989; 57:495-501.
63. Levine MM, Kaper JB, Herrington D, et al. Volunteer studies of deletion mutants of Vibrio cholerae O1 prepared by recombinant techniques. Infect Immun 1988 56:161-167.
64. Mekalanos JJ, Swartz DJ, Pearson GD, et al. Cholera toxin genes: nucleotide sequence, deletion analysis and vaccine development. Nature 1983; 306:551-557.
65. Taylor R, Shaw C, Heterson K, et al. Safe, live Vibrio cholerae vaccines? Vaccine 1988; 6:151-154.
66. Miller JF, Mekalanos JJ, Falkow S. Coordinate regulation and sensory transduction in the control of bacterial virulence. Science 1989; 243:916-922.
67. Herrington DA, Hall RH, Losonsky G, et al. Toxin, toxin-coregulated pili, and the toxR regulon are essential for Vibrio cholerae pathogenesis in humans. J Exp Med 1988; 168:1487-1492.
68. Tacket CO, Losonsky G, Nataro JP, et al. Safety and immunogenicity of live oral cholera vaccine candidate CVD 110, a ΔctxA Δzot Δace derivative of El Tor Ogawa Vibrio cholerae. J Infect Dis 1993; 168:1536-1540.
69. O'Brien AD, Chen ME, Holmes RK, et al. Environmental and human isolates of Vibrio cholerae and Vibrio parahaemolyticus produce a Shigella dysenteriae 1 (Shiga)-like cycotoxin. Lancet 1984; 1:77-78.
70. Levine MM, Kaper JB, Herrington D, et al. Safety, immunogenicity, and efficacy of recombinant live oral cholera vaccines, CVD 103 and CVD 103-HgR. Lancet 1988; 2:467-470.
71. Ketley JM, Michalski J, Galen J, et al. Construction of genetically marked Vibrio cholerae O1 vaccine strains [published erratum appears in FEMS Microbiol Lett 1998 Jun 15; 163(2):269]. FEMS Microbiol Lett 1993; 111:15-21.
72. Kaper JB, Levine MM. Recombinant attenuated Vibrio cholerae strains used as live oral vaccines. Res Microbiol 1990; 141:901-906.
73. Ketley JM, Kaper JB, Herrington DA, et al. Diminished immunogenicity of a recombination-deficient derivative of Vibrio cholerae vaccine strain CVD103. Infect Immun 1990; 58:1481-1484.
74. Cryz SJJ, Levine MM, Losonsky G, et al. Safety and immunogenicity of a booster dose of Vibrio cholerae CVD 103- HgR live oral cholera vaccine in Swiss adults. Infect Immun 1992; 60:3916-3917.
75. Cryz SJJ, Levine MM, Kaper JB, et al. Randomized double-blind placebo controlled trial to evaluate the safety and immunogenicity of the live oral cholera vaccine strain CVD 103-HgR in Swiss adults. Vaccine 1990; 8:577-580.
76. Kotloff KL, Wasserman SS, O'Donnell S, et al. Safety and immunogenicity in North Americans of a single dose of live oral cholera vaccine CVD 103-HgR: results of a randomized, placebo- controlled, double-blind crossover trial. Infect Immun 1992; 60:4430-4432.
77. Levine MM, Kaper JB. Live oral vaccines against cholera: an update. Vaccine 1993; 11:207-212.
78. Su-Arehawaratana P, Singharaj P, Taylor DN, et al. Safety and immunogenicity of different immunization regimens of CVD 103- HgR live oral cholera vaccine in soldiers and civilians in Thailand. J Infect Dis 1992; 165:1042-1048.
79. Suharyono, Simanjuntak C, Witham N. et al. Safety and immunogenicity of single-dose live oral cholera vaccine CVD 103-HgR in 5-9-year-old Indonesian children. Lancet 1992; 3411:689-694.
80. Tacket CO, Losonsky G, Nataro JP, et al. Onset and duration of protective immunity in challenged volunteers after vaccination with live oral cholera vaccine CVD 103-HgR. J Infect Dis 1992; 166:837-841.
81. Migasena S, Pitisuttitham P, Prayurahong B, et al. Preliminary assessment of the safety and immunogenicity of live oral cholera vaccine strain CVD 103-HgR in healthy Thai adults. Infect Immun 1989; 57:3261-3264.
82. Simanjuntak CH, O'Hanley P, Punjabi NH, et al. Safety, immunogenicity, and transmissibility of single-dose live oral cholera vaccine strain CVD 103-HgR in 24- to 59-month-old Indonesian children. J Infect Dis 1993; 168:1169-1176.
83. Gotuzzo E, Butron B, Seas C, et al. Safety, immunogenicity, and excretion pattern of single-dose live oral cholera vaccine CVD 103-HgR in Peruvian adults of high and low socioeconomic levels. Infect Immun 1993; 61:3994-3997.
84. Tacket CO, Cohen MB, Wasserman SS, et al. Randomized, double-blind, placebo-controlled, mukicentered trial of the efficacy of a single dose of live oral cholera vaccine CVD 103-HgR in preventing cholera following challenge with Vibrio cholerae O1 El Tor Inaba three months after vaccination. Infect Immun 1999; 67:6341-6345.
85. Losonsky GA, Tacket CO, Wasserman SS, et al. Secondary Vibrio cholera-specific cellular antibody responses following wild-type homologous challenge in people vaccinated with CVD 103-HgR live oral cholera vaccine: changes with time and lack of correlation with protection. Infect Immun 1993; 61:729-733.
86. Losonsky GA, Yunyongying J, Lim V, et al. Factors influencing secondary vibriocidal immune responses: relevance for understanding immunity to cholera. Infect Immun 1996; 64:10-15.
87. Lagos R, Fasano A, Wasserman SS, et al. Effect of small bowel bacterial overgrowth on the immunogenicity of single-dose live oral cholera vaccine CVD 103-HgR. J Infect Dis 1999; 180:1709-1712.
88. Richie EE, Punjabi NH, Sidharta YY, et al. Efficacy trial of single-dose live oral cholera vaccine CVD 103-HgR in North Jakarta, Indonesia, a cholera endemic area. Vaccine 2000; 18:2399-2410.
89. Perry RT, Plowe CV, Koumare B, et al. A single dose of live oral cholera vaccine CVD 103-HgR is safe and imnmnogenic inm HIV-infected and HIV-noninfected adults in Mali. Bull World Health Organ 1998; 76:63-71.
90. Kollaritsch H, Cryz SJ Jr, Lang AB, et al. Local and systemic immune responses to combined Vibrio cholerae CVD103-HgR and Salmonella typhi Ty21a live oral vaccines after primary immunization and reimmunication. Vaccine 2000; 18:3031-3039.
91. Kollaritsch H, Purer E, Herzog C, et al. Randomized, double-blind placebo-controlled trial to evaluate the safety and immunogenicity of combined Salmonella typhi Ty21a and Vibrio cholerae CVD 103-HgR live oral vaccines. Infect Immun 1996; 64:1454-1457.
92. Michalski J, Galen JE, Fasano A, Kaper JB. CVD110, an attenuated Vibrio cholerae O1 El Tor live oral vaccine strain. Infect Immun 1993; 61:4462-4468.
93. Pearson GD, Woods A, Chiang SL, Mekalanos JJ. CTX genetic element encodes a site-specific recombination system and an intestinal colonization factor [published erratum appears in Proc Natl Acad Sci USA 1993 Sep 1;90(17):8302]. Proc Natl Acad Sci USA 1993; 90:3750-3754.
94. Taylor DN, Killeen KP, Hack DC, et al. Development of a live, oral, attenuated vaccine against El Tor cholera. J Infect Dis 1994; 170:1518-1523.
95. Kenner JR, Coster TS, Taylor DN, et al. Peru-15, an improved live attenuated oral vaccine candidate for Vibrio cholerae O1. J Infect Dis 1995; 172:1126-1129.
96. Coster TS, Killeen KP, Waldor MK, et al. Safety, immunogenicity, and efficacy of live attenuated Vibrio cholerae O139 vaccine prototype. Lancet 1995; 345:949-952.
97. Chiang SL, Mekalanos JJ. Construction of a Vibrio cholerae vaccine candidate using transposon delivery and FLP recombinase-mediated excision. Infect Immun 2000; 68:6391-6397,
98. Taylor DN, Tacket CO, Losonsky G, et al. Evaluation of a bivalent (CVD 103-HgR/CVD 111) live oral cholera vaccine in adult volunteers from the United States and Peru. Infect Immun 1997; 65:3852-3856.
99. Taylor DN, Sanchez JL, Castro JM, et al. Expanded safety and immunogenicity of a bivalent, oral, attenuated cholera vaccine, CVD 103-HgR plus CVD 111, in United States military personnel stationed in Panama. Infect Immun 1999; 67:2030-2034.
100. Mazel D, Dychinco B, Webb VA, Davies J. A distinctive class of integron in the Vibrio cholerae genome. Science 1998; 280:605-608.
101. Ryan ET, Bridges EA, Crean TI, et al. Local production of anti- Vibrio cholerae mucosal antibody in reproductive tract tissues following cholera. (submitted).
102. Levine MM, Black RE, Clements ML, et al. Duration of infection-derived immunity to cholera. J Infect Dis 1981; 143:818-820.
103. Tacket CO, Losonsky G, Nataro JP, et al. Initial clinical studies of CVD 112 Vibrio cholerae O139 live oral vaccine: safety and efficacy against experimental challenge. J Infect Dis 1995; 172:883-886.
104. Waldor MK, Mekalanos JJ. Emergence of a new cholera pandemic: molecular analysis of virulence determinants in Vibrio cholerae O139 and development of a live vaccine prototype. J Infect Dis 1994; 170:278-283.
105. Butterton JR, Boyko SA, Calderwood SB. Use of the Vibrio cholerae irgA gene as a locus for insertion and expression of heterologous antigens in cholera vaccine strains. Vaccine 1993; 11:1327-1335.
106. Ryan ET, Butterton JR, Smith RN, et al. Protective immunity against Clostridium difficile toxin A induced by oral immunization with a live, attenuated Vibrio cholerae vector strain. Infect Immun 1997; 65:2941-2949.
107. Acheson DW, Levine MM, KaperJB, Keusch GT. Protective immunity to Shiga-like toxin I following oral immunization with Shiga-like toxin I B-subunit-producing Vibrio cholerae CVD 103-HgR. Infect Immun 1996; 64:355-357.
108. Ryan ET, Butterton JR, Zhang T, et al. Oral immunization with attenuated vaccine strains of Vibrio cholerae expressing a dodecapeptide repeat of the serine-rich Entamoeba histolytica protein fused to the cholera toxin B subunit induces systemic and mucosal antiamebic and anti- V. cholerae antibody responses in mice. Infect Immun 1997; 65:3118-3125.
109. Butterten JR, Ryan ET, Acheson DW, Calderwood SB. Coexpression of the B subumt of Shiga toxin 1 and EaeA from enterohemorrhagic Escherichia coli in Vibrio cholerae vaccine strains. Infect Immun 1997; 65:2127-2135.
110. Butterton JR, Beattie DT, Gardel CL, et al. Heterologous antigen expression in Vibrio cholerae vector strains. Infect Immun 1995; 63:2689-2696.
111. Viret JF, Cryz SJJ, Favre D. Expression ot Shigella sonnei lipopolysaccharide in Vibrio cholerae. Mol Microbiol 1996; 19:949-963.
112. Favre D, Cryz SJJ, Viret JF. Development of Shigella sonnei live oral vaccines based on defined rfb Inaba deletion mutants of Vibrio cholerae expressing the Shigella serotype D O polysaccharide. Infect Immun 1996; 64:576-584.
113. Viret JF, Cryz SJJ, Lang AB, Favre D. Molecular cloning and characterization of the genetic determinants that express the complete Shigella serotype D (Shigella sonnei) lipopolysaccharide in heterologous live attenuated vaccine strains. Mol Microbiol 1993; 7:239-252.
114. Ryan ET, Crean TI, John M, et al. In vivo expression and immunoadjuvancy of a mutant ot heat-labile enterotoxin of Escherichia coli in vaccine and vector strains of Vibrio cholerae. Infect Immun 1999; 67:1694-1701.
115. Ryan ET, Crean TI, Kochi SK, et al. Development of a ΔglnA balanced lethal plasimd system for expression of heterologous antigens by attenuated vaccine vector strains of Vibrio cholerae. Infect Immun 2000; 68:221-226.
116. John M, Crean TI, Calderwood SB, Ryan ET. In vitro and in vivo analyses of constitutive and in vivo-induced promoters in attenuated vaccine and vector strains of Vibrio cholerae. Infect Immun 2000; 68:1171-1175.
117. Butterton JR, Ryan ET, Shahin RA, Calderwood SB. Development of a germfree mouse model of Vibrio cholerae infection. Infect Immun 1996; 64:4373-4377.
118. Crean TI, John M, Calderwood SB, Ryan ET. Optimizing the germfree mouse model for in vivo evaluation of oral Vibrio cholerae vaccine and vector strains. Infect Immun 2000; 68:977-981.